New Study Links Psilocybin to Lower Risk of Opioid Addiction
Researchers attempt to replicate findings from a 2017 study that found classic psychedelic use conferred reduced risk of past-year opioid dependence and abuse.
Entries by Greg Gilman
Psychedelic Business Spotlight – April 8
This week in psychedelic business news: Field Trip Health secures a patent; Core One Labs seeks more retail investors; a new CEO takes over GABA Therapeutics.
Oregon Psilocybin Rules ‘May Have a Negative Impact on Lower Income Individuals’
The State acknowledges proposed psilocybin services rules will incur costs that “could ultimately be passed onto clients.”
Psychedelic Business Spotlight – April 1
This week in psychedelic business news: TripSitter expands; Enveric files a major patent; and Psychedelic Water raises its profile.
Psychedelic Business Spotlight – March 25
This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles.
Psychedelic Business Spotlight – March 18
This week in psychedelic business news: A psychedelics company folds; Ketamine Wellness Centers expand; Nova Mentis funds psilocybin studies.
Mind Cure Health Halts All Psychedelic Business Activity
The company was pursuing several psychedelic business strategies, including synthesizing ibogaine for researchers.
Psychedelic Business Spotlight- March 11
This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves a psilocybin PTSD study.
Psychedelic Business Spotlight – March 4
This week in psychedelic business news: Field Trip partners with Cerebral; Benzinga forms Psychedelic Advisory Council; Incannex pursues virtual reality psychedelic therapy.
The Biggest Reason People in Oregon Want to Use Psilocybin
Spoiler alert: It’s not because they’re depressed.
